Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

JUPITER, Fla. – (NewMediaWire) – November 16, 2021 – Marizyme Inc. (“Marizyme
or the “Company”) (OTCQB:MRZM),
is pleased to announce the hiring of Mr. David Barthel as the Chief
Executive Officer for Marizyme. In his role Mr. Barthel will look to advance
the Company’s technology pipeline and stay committed to
commercialization efforts of DuraGraft in Europe and Asia while focusing on the
FDA submissions for DuraGraft and MATLOC 1 in the US. In addition, Mr. Barthel
will lead the Company through its financing initiatives, strengthening the financial position of the Company in preparation
for an anticipated Nasdaq listing in 2022.

Barthel founded The SmartPill Corp. and led the company as CEO & President
until its acquisition by medical device giant, Medtronic. Mr. Barthel
successfully took The SmartPill company, developing an innovative ingestible sensor-based
capsule for diagnosing GI motility disorders, from its initial patent, through
the entire product development process, raising more than $70 million in
multiple funding rounds. Mr. Barthel led his team through multiple clinical
trials, manufacturing, FDA approval, commercialization and successful insurance
reimbursement.  After the acquisition by
Medtronic, Mr. Barthel joined the company as Area Vice President, GIH Southeast


recently, Mr. Barthel was CEO of Health Logic Interactive Inc. (“Health
”) and its wholly owned Subsidiary, My Health Logic Inc. (“My Health
”), a company focused on developing an innovative point-of-care lab-on-chip
digital diagnostic device technologies for chronic kidney disease.  In less than a year, Mr. Barthel led the Company
from an initial patent pending technology with proof-of-concept data to
building an IP portfolio and further advancing our lab-on-chip technology platform.
The Company also began development on its point-of-care device, MATLOC 1, which
is expected to have a functional prototype ready for its clinical trials to
take place in Q3 2022. Mr. Barthel was responsible for implementing product and
software development partners, the preparation of an FDA pre-submission,
leading discussions with several potential strategic partners, integrating a
strong clinical and business team-based culture, and a diverse Scientific
Advisory Board. He has also developed the business plan around the utilization
of multiple partners for commercialization with the potential for multiple
revenue streams that will ensure eventual success of the device. My Health
Logic Inc., subsidiary of Health Logic which holds the MATLOC device technology
and all accompanying agreements, is currently in the process of being acquired
by Marizyme.


Barthel earned a Bachelor of Arts Degree from St. Norbert College in De Pere,
Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest,


Dr. Vithal Dhaduk, (Chairman) of the Board of Directors, stated the
following: “
We are very
excited about acquiring My Health Logic and David Barthel becoming our CEO. My
Health Logic developed the MATLOC technology, an innovative technology
that has strong potential to improve the lives of millions of patients
with chronic kidney disease.  Bringing on the very dedicated and effective
management group led by David Barthel will add strength to Marizyme’s
current team.

This is a very strategic step for Marizyme to diversify and improve
Marizyme’s current product portfolio by adding more innovative,
platform technologies and a strong management team. We are looking forward
to bringing these new technologies to the market to serve a unique and unmet
need in the chronic kidney and cardiac disease population.”  

About Marizyme, Inc.

Marizyme is an
integrated life sciences company dedicated to the acquisition, development and
commercialization of therapies that minimize mortality and costs in the acute
care space. The Company’s flagship product, DuraGraft®, is an
intra-operative vascular graft storage solution that inhibits endothelial
damage and leads to improved clinical outcomes by reducing the incidence of
complications associated with vein graft failure in bypass surgery. DuraGraft
enhances coronary artery bypass grafting (CABG) surgical outcomes by
significantly reducing major adverse cardiac events such as repeat
revascularization and myocardial infarction. DuraGraft is approved for use in
the EU and several Asian countries but is not yet approved for use in the U.S.
Marizyme is also focused on the development and marketing of products based on
its clinically tested and previously patented protease based therapeutic
Krillase® platform. Krillase is not approved for use in the
U.S. For more information about Marizyme, visit

Forward-Looking Statements

This press release may contain
certain forward-looking statements, including those relating to the Marizyme’s
product development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of operations,
business strategies, potential growth 
opportunities and other statements that are predictive in nature. The
Company has made every reasonable effort to ensure the information and
assumptions on which these statements are based are current, reasonable, and
complete. However, a variety of factors, many of which are beyond the  Company’s control, affect the Company’s
operations, performance, business strategy and results and  there can be no assurances that the Company’s
actual results will not differ materially from those indicated herein.
Additional written and oral forward-looking statements may be made by the
Company from time to time. Forward-looking statements may be identified by the
use of forward-looking expressions, including, but not limited to, “expect,”
“anticipate,” “intend,” “plan,” “believe,” “estimate,”  “potential,” “predict,” “project,” “should,”
“would” and similar expressions and the negatives of those terms. These
statements relate to future events or our financial performance and involve
known and  unknown risks, including those
risks set forth in the Company’s risk factor disclosure in the reports that
Marizyme files with the Securities and Exchange Commission (SEC File No.
000-53223), uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.


Bradley Richmond